SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer

Inclusion Criteria: * Age ≥18 years, male or female. * Baseline ECOG performance status 0-1. * Histologically or cytologically confirmed unresectable stage III NSCLC * Life expectancy ≥3 months * No prior anti-tumor therapy * No known EGFR/ALK/ROS1 sensitive mutations * At least one measurable lesion according to RECIST v1.1 * Adequate organ function * Signed informed consent Exclusion Criteria: * Mixed small-cell and non-small-cell lung cancer histology * Known EGFR/ALK/ROS1 mutations * Prior systemic anti-cancer therapy within 4 weeks * Active autoimmune disease requiring systemic treatment * Active infection including uncontrolled HBV, HCV or HIV infection * Significant cardiovascular disease * Uncontrolled hypertension * Pregnancy or breastfeeding * Participation in another interventional clinical trial